Microneedle Array for Influenza Vaccine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current influenza vaccines, particularly the inactivated split vaccine, have low efficacy and insufficient antibody production, necessitating a more efficient and simple administration method, especially during pandemics when immunity needs to be induced in many people with a small amount of vaccine.
Innovation Solution
A microneedle array is developed containing an inactivated whole virion influenza vaccine with a water-soluble polymer needle portion that dissolves after insertion, combined with a sheet portion, allowing for improved antibody production and simpler vaccine administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If an inactivated split vaccine is used for influenza vaccination, then the vaccine can be administered widely, but the antibody production ability is insufficient and efficacy is low
Solution Approach 1:
The patent changes the vaccine formulation from split vaccine to inactivated whole virion vaccine, and changes the administration route from conventional injection to microneedle array. These parameter changes result in significantly enhanced antibody production while maintaining wide applicability
Solution Approach 2:
The microneedle array concentrates the vaccine delivery to specific localized sites in the skin, creating high local concentration of the inactivated whole virion vaccine at the application site, which then triggers systemic immune response with higher antibody production
2Reliability
If a conventional injection method is used for vaccine administration, then the vaccine can be delivered effectively, but the administration operation is complex and requires medical professionals
Solution Approach 1:
The patent replaces the complex mechanical injection system (syringe, needle, injection technique) with a microneedle array system that dissolves in the skin, eliminating the need for injection skills and medical professional intervention while maintaining effective vaccine delivery
Solution Approach 2:
The microneedle array is designed to be self-administered by dissolving in the skin upon contact, releasing the vaccine automatically without requiring manual injection operations. The system serves itself by converting from a solid needle array to a dissolved state that releases the vaccine payload
3Reliability
If a large amount of vaccine is administered to induce immunity in many people, then sufficient immune response can be achieved, but the vaccine supply is insufficient during pandemics
Solution Approach 1:
The patent changes the vaccine type to inactivated whole virion vaccine and the delivery system to microneedle array, which together enable achieving sufficient immune response with significantly reduced vaccine dosage compared to conventional split vaccines administered by injection
Solution Approach 2:
The microneedle array creates high local concentration of vaccine at the skin application site, maximizing the immunogenic effect per unit dose. This localized high concentration approach allows pandemic-scale immunity induction with limited vaccine supply
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microneedle array significantly enhances antibody production and vaccine efficacy, even with a small amount of vaccine, compared to traditional injection methods, and can be administered in a simpler operation, stimulating immune response and increasing serum IgG antibody titers.
Implementation Method 1
the needle portion contains a water-soluble polymer and dissolves after being inserted into a body
Data Source
Figure 1
Figure 2~3
Figure 4~5
AI summary
Provided is a microneedle array which can improve an antibody production ability and makes it possible to simply administer an influenza vaccine. The microneedle array includes a needle portion, which contains an inactivated whole virion influenza vaccine, and a sheet portion. Also provided is an administration method in which the microneedle array is administered and then administered secondly after an interval of equal to or greater than 24 hours and less than 2 months.